Nicotine percentage replacement among smokeless tobacco users with nicotine patch

Jon Owen Ebbert, Jason A. Post, Thomas P. Moyer, Lowell C. Dale, Darrell R. Schroeder, Richard D. Hurt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To obtain preliminary evidence on the safety and efficacy of high dose nicotine patch therapy among smokeless tobacco (ST) users who consume ≥3 cans of ST per week, we conducted a randomized, placebo-controlled clinical trial with 42 ST users randomized to nicotine patch doses of 21, 42, and 63 mg/day or placebo. Serum nicotine concentrations were measured during ad libitum ST use and nicotine replacement therapy, and percentages of nicotine replacement were calculated. We observed substantial inter-subject variability in nicotine concentrations with ad lib ST use. The mean percentage replacement of ad lib ST use serum nicotine concentrations approximated 100% with the 42 mg/day patch dose (mean ± S.D., 98.4% ± 45%). Dosing with the 21 mg/day nicotine patch was associated with mean "under-replacement" (53.2% ± 17.1%), and the 63 mg/day nicotine was associated with mean "over-replacement" (159.2% ± 121.9%). We observed symptoms of nausea consistent with nicotine toxicity in two subjects in the 63 mg/day group while no subjects in the 42 mg/day reported these symptoms. We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use ≥3 cans/week.

Original languageEnglish (US)
Pages (from-to)223-226
Number of pages4
JournalDrug and Alcohol Dependence
Volume89
Issue number2-3
DOIs
StatePublished - Jul 10 2007

Fingerprint

Tobacco Use Cessation Products
Smokeless Tobacco
Nicotine
nicotine
Tobacco Use
Placebos
Therapeutics
Serum
Nausea
Toxicity
Randomized Controlled Trials
Safety

Keywords

  • Administration
  • Cutaneous
  • Nicotine
  • Randomized clinical trial
  • Smokeless tobacco
  • Tobacco alkaloid
  • Tobacco use cessation

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Nicotine percentage replacement among smokeless tobacco users with nicotine patch. / Ebbert, Jon Owen; Post, Jason A.; Moyer, Thomas P.; Dale, Lowell C.; Schroeder, Darrell R.; Hurt, Richard D.

In: Drug and Alcohol Dependence, Vol. 89, No. 2-3, 10.07.2007, p. 223-226.

Research output: Contribution to journalArticle

Ebbert, Jon Owen ; Post, Jason A. ; Moyer, Thomas P. ; Dale, Lowell C. ; Schroeder, Darrell R. ; Hurt, Richard D. / Nicotine percentage replacement among smokeless tobacco users with nicotine patch. In: Drug and Alcohol Dependence. 2007 ; Vol. 89, No. 2-3. pp. 223-226.
@article{2669e991c9114aaba35842ef78b43dd9,
title = "Nicotine percentage replacement among smokeless tobacco users with nicotine patch",
abstract = "To obtain preliminary evidence on the safety and efficacy of high dose nicotine patch therapy among smokeless tobacco (ST) users who consume ≥3 cans of ST per week, we conducted a randomized, placebo-controlled clinical trial with 42 ST users randomized to nicotine patch doses of 21, 42, and 63 mg/day or placebo. Serum nicotine concentrations were measured during ad libitum ST use and nicotine replacement therapy, and percentages of nicotine replacement were calculated. We observed substantial inter-subject variability in nicotine concentrations with ad lib ST use. The mean percentage replacement of ad lib ST use serum nicotine concentrations approximated 100{\%} with the 42 mg/day patch dose (mean ± S.D., 98.4{\%} ± 45{\%}). Dosing with the 21 mg/day nicotine patch was associated with mean {"}under-replacement{"} (53.2{\%} ± 17.1{\%}), and the 63 mg/day nicotine was associated with mean {"}over-replacement{"} (159.2{\%} ± 121.9{\%}). We observed symptoms of nausea consistent with nicotine toxicity in two subjects in the 63 mg/day group while no subjects in the 42 mg/day reported these symptoms. We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use ≥3 cans/week.",
keywords = "Administration, Cutaneous, Nicotine, Randomized clinical trial, Smokeless tobacco, Tobacco alkaloid, Tobacco use cessation",
author = "Ebbert, {Jon Owen} and Post, {Jason A.} and Moyer, {Thomas P.} and Dale, {Lowell C.} and Schroeder, {Darrell R.} and Hurt, {Richard D.}",
year = "2007",
month = "7",
day = "10",
doi = "10.1016/j.drugalcdep.2006.12.034",
language = "English (US)",
volume = "89",
pages = "223--226",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Nicotine percentage replacement among smokeless tobacco users with nicotine patch

AU - Ebbert, Jon Owen

AU - Post, Jason A.

AU - Moyer, Thomas P.

AU - Dale, Lowell C.

AU - Schroeder, Darrell R.

AU - Hurt, Richard D.

PY - 2007/7/10

Y1 - 2007/7/10

N2 - To obtain preliminary evidence on the safety and efficacy of high dose nicotine patch therapy among smokeless tobacco (ST) users who consume ≥3 cans of ST per week, we conducted a randomized, placebo-controlled clinical trial with 42 ST users randomized to nicotine patch doses of 21, 42, and 63 mg/day or placebo. Serum nicotine concentrations were measured during ad libitum ST use and nicotine replacement therapy, and percentages of nicotine replacement were calculated. We observed substantial inter-subject variability in nicotine concentrations with ad lib ST use. The mean percentage replacement of ad lib ST use serum nicotine concentrations approximated 100% with the 42 mg/day patch dose (mean ± S.D., 98.4% ± 45%). Dosing with the 21 mg/day nicotine patch was associated with mean "under-replacement" (53.2% ± 17.1%), and the 63 mg/day nicotine was associated with mean "over-replacement" (159.2% ± 121.9%). We observed symptoms of nausea consistent with nicotine toxicity in two subjects in the 63 mg/day group while no subjects in the 42 mg/day reported these symptoms. We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use ≥3 cans/week.

AB - To obtain preliminary evidence on the safety and efficacy of high dose nicotine patch therapy among smokeless tobacco (ST) users who consume ≥3 cans of ST per week, we conducted a randomized, placebo-controlled clinical trial with 42 ST users randomized to nicotine patch doses of 21, 42, and 63 mg/day or placebo. Serum nicotine concentrations were measured during ad libitum ST use and nicotine replacement therapy, and percentages of nicotine replacement were calculated. We observed substantial inter-subject variability in nicotine concentrations with ad lib ST use. The mean percentage replacement of ad lib ST use serum nicotine concentrations approximated 100% with the 42 mg/day patch dose (mean ± S.D., 98.4% ± 45%). Dosing with the 21 mg/day nicotine patch was associated with mean "under-replacement" (53.2% ± 17.1%), and the 63 mg/day nicotine was associated with mean "over-replacement" (159.2% ± 121.9%). We observed symptoms of nausea consistent with nicotine toxicity in two subjects in the 63 mg/day group while no subjects in the 42 mg/day reported these symptoms. We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use ≥3 cans/week.

KW - Administration

KW - Cutaneous

KW - Nicotine

KW - Randomized clinical trial

KW - Smokeless tobacco

KW - Tobacco alkaloid

KW - Tobacco use cessation

UR - http://www.scopus.com/inward/record.url?scp=34248580112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248580112&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2006.12.034

DO - 10.1016/j.drugalcdep.2006.12.034

M3 - Article

C2 - 17300878

AN - SCOPUS:34248580112

VL - 89

SP - 223

EP - 226

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 2-3

ER -